Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Eledon Pharmaceuticals Inc ELDN

Healthcare Biotechnology
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L... see more

Recent & Breaking News (NDAQ:ELDN)

Novus Therapeutics Reports Third Quarter 2018 Financial Results

Business Wire November 13, 2018

Novus Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Business Wire September 26, 2018

Novus Therapeutics to Postpone Offering of Common Stock

Business Wire September 7, 2018

Novus Therapeutics Announces Proposed Public Offering of Common Stock

Business Wire September 4, 2018

Novus Therapeutics Reports Second Quarter 2018 Financial Results

Business Wire August 7, 2018

Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media

Business Wire June 19, 2018

Novus Therapeutics Reports First Quarter 2018 Financial Results

Business Wire May 11, 2018

Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

Business Wire April 2, 2018

Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference

PR Newswire November 21, 2017

Novus Therapeutics Reports Third Quarter 2017 Results

PR Newswire November 8, 2017

Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President

PR Newswire November 6, 2017

Novus Therapeutics Reports Second Quarter 2017 Results

PR Newswire August 9, 2017

Novus Therapeutics Announces Change in Management

PR Newswire July 10, 2017

Novus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire June 12, 2017